While the tumor-specific frequency of CREBBP and EP300 mutations constrains the analysis in small cohorts, these findings further support their role as biomarkers of immunotherapy response and underscore the need for expanded datasets and prospective validation. This evidence concerns the gene CREBBP and neoplasm.